Imris (OTCMKTS:IMRSQ) versus Tandem Diabetes Care (NASDAQ:TNDM) Critical Comparison

Tandem Diabetes Care (NASDAQ:TNDM) and Imris (OTCMKTS:IMRSQ) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Valuation & Earnings

This table compares Tandem Diabetes Care and Imris”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.03 billion	1.03	-$204.71 million	($1.40)	-11.06
Imris	N/A	N/A	N/A	N/A	N/A

Imris has lower revenue, but higher earnings than Tandem Diabetes Care.

Profitability

This table compares Tandem Diabetes Care and Imris’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-9.20%	-53.10%	-8.50%
Imris	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings for Tandem Diabetes Care and Imris, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1	9	8	2	2.55
Imris	0	0	0	0	0.00

Tandem Diabetes Care presently has a consensus target price of $30.16, suggesting a potential upside of 94.82%. Given Tandem Diabetes Care’s stronger consensus rating and higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than Imris.

Summary

Tandem Diabetes Care beats Imris on 5 of the 8 factors compared between the two stocks.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

About Imris

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Its VISIUS Surgical Theatre incorporates magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites to provide intraoperative imaging for specific medical applications by bringing advanced imaging into the operating room (OR). The company sells the VISIUS Surgical Theatres to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular, and cardiovascular markets. It also provides service and extended maintenance contracts, and accessories and disposables. The company was founded in 2005 and is based in Winnipeg, Canada.